Innovations + Investments in Healthcare Summit 2015


AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:

AstraZeneca RSS Channel

Title Filter      Display #  
# Article Title
1 AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
2 AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa
3 AstraZeneca completes agreement with Tillotts Pharma for Entocort
4 IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer
5 AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma
6 AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
7 AstraZeneca provides update on brodalumab development programme
8 AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden
9 AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits
10 FDA grants Priority Review for potential new indication for Brilinta
11 AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology
12 AstraZeneca and PatientsLikeMe announce global research collaboration
13 AstraZeneca joins Genomics England consortium
14 AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes
15 AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD
16 PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack
17 AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada
18 AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
19 AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform
20 MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]